Prof. Michael Berndt, new Director of the Biomedical Diagnostics Institute

THE BDI WELCOMES NEW DIRECTOR

09.10



The Biomedical Diagnostics Institute welcomes Prof. Michael Berndt as its new Director. Michael’s research interests include thrombosis, inflammation and vascular biology. He also holds the position of Professor of Experimental Medicine at the Royal College of Surgeons in Ireland.

Previously, Michael was Head of the College of Medicine and Health, University College Cork, Ireland and Interim Director of the Biosciences Institute, UCC.

Michael has received numerous national and international research awards, including the Glaxo Wellcome Medal in 1996 and a Distinguished Career Award from the International Society on Thrombosis and Haemostasis in 2003. He serves on several editorial boards, including the Journal of Thrombosis and Haemostasis and Arteriosclerosis Thrombosis & Vascular Biology. He has published over 270 papers (h-index = 63, >11,000 citations), including major international journals, such as Science, Journal of Experimental Medicine and Blood.

He has collaborated with pharmaceutical companies including E. Merck and Hoffman-la-Roche, and has filed a number of patents, including one licensed to Genetics Institute (Wyeth).  He was a co-founder of the ASX-listed proteomics-based biotechnology company, Cryptome Pharmaceuticals Ltd (now Healthlinx). 

Michael is Chairman elect of the Executive Council of the International Society on Thrombosis and Haemostasis. He was Programme Chair for the XXth Congress of the International Society on Thrombosis and Haemostasis, Sydney, 2005 and the XVth International Vascular Biology Meeting, Sydney, 2008.